Giacomo Ruotolo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/118449/publications.pdf

Version: 2024-02-01

47 papers	3,740 citations	172386 29 h-index	214721 47 g-index
49 all docs	49 docs citations	49 times ranked	5225 citing authors

#	Article	IF	Citations
1	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 2017, 376, 1933-1942.	13.9	593
2	Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease in Nondiabetic American Indians: The Strong Heart Study. Diabetes Care, 2003, 26, 861-867.	4.3	376
3	Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals. Diabetes Care, 2011, 34, 210-215.	4.3	335
4	Alimentary Lipemia, Postprandial Triglyceride-Rich Lipoproteins, and Common Carotid Intima-Media Thickness in Healthy, Middle-Aged Men. Circulation, 1999, 100, 723-728.	1.6	229
5	Fatty liver index and mortality: The cremona study in the 15th year of follow-up. Hepatology, 2011, 54, 145-152.	3.6	208
6	The Molecular Basis of Lecithin:Cholesterol Acyltransferase Deficiency Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1972-1978.	1.1	158
7	Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Journal of the American College of Cardiology, 1998, 32, 1648-1656.	1.2	155
8	Dyslipidemia of the metabolic syndrome. Current Cardiology Reports, 2002, 4, 494-500.	1.3	132
9	Fasting Plasma Leptin, Tumor Necrosis Factor-Â Receptor 2, and Monocyte Chemoattracting Protein 1 Concentration in a Population of Glucose-Tolerant and Glucose-Intolerant Women: Impact on cardiovascular mortality. Diabetes Care, 2003, 26, 2883-2889.	4.3	117
10	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. Journal of the American College of Cardiology, 2015, 66, 2201-2210.	1.2	105
11	Human Evidence That the Apolipoprotein A-II Gene Is Implicated in Visceral Fat Accumulation and Metabolism of Triglyceride-Rich Lipoproteins. Circulation, 2001, 104, 1223-1228.	1.6	96
12	Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetologica, 2012, 49, 421-428.	1.2	89
13	Dietary Intakes Vary with Age among Eskimo Adults of Northwest Alaska in the GOCADAN Study, 2000â€“2003. Journal of Nutrition, 2005, 135, 856-862.	1.3	83
14	The dual glucoseâ€dependent insulinotropic peptide and glucagonâ€like peptideâ€1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2451-2459.	2.2	83
15	Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. Journal of the American College of Cardiology, 2000, 35, 647-654.	1.2	81
16	Association Between Plasma Monocyte Chemoattractant Protein-1 Concentration and Cardiovascular Disease Mortality in Middle-Aged Diabetic and Nondiabetic Individuals. Diabetes Care, 2009, 32, 2105-2110.	4.3	80
17	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. American Heart Journal, 2015, 170, 1061-1069.	1.2	74
18	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. JAMA Cardiology, 2020, 5, 1136.	3.0	59

#	Article	IF	Citations
19	Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes. Metabolism: Clinical and Experimental, 1990, 39, 598-604.	1.5	55
20	A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. International Journal of Circumpolar Health, 2005, 64, 206-221.	0.5	52
21	Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 363-378.	1.8	49
22	The dual glucoseâ€dependent insulinotropic polypeptide and glucagonâ€like peptideâ€1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p<scp>ost hoc</scp> analysis. Diabetes, Obesity and Metabolism, 2022, 24, 148-153.	2.2	48
23	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 943-952.	2.9	42
24	ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. JAMA Cardiology, 2018, 3, 401.	3.0	42
25	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Annals of the Rheumatic Diseases, 2018, 77, 988-995.	0.5	41
26	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis, 2017, 261, 12-18.	0.4	32
27	Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C. Cardiovascular Revascularization Medicine, 2007, 8, 15-20.	0.3	31
28	Evidence that apolipoprotein(a) phenoptype is a risk factor for coronary artery disease in men < 55 years of age. American Journal of Cardiology, 1994, 74, 346-351.	0.7	30
29	Potent peroxisome proliferator-activated receptor-Â agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. European Heart Journal, 2015, 36, 3020-3022.	1.0	29
30	The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. Atherosclerosis, 2009, 206, 298-302.	0.4	28
31	Efficacy, Safety, Tolerability, and Pharmacokinetic Profile of Evacetrapib Administered as Monotherapy or in Combination With Atorvastatin in Japanese Patients With Dyslipidemia. American Journal of Cardiology, 2014, 113, 2021-2029.	0.7	27
32	Effects of a cardioselective Î²-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middle-aged men with modestly increased cardiovascular risk. Atherosclerosis, 1998, 137, 391-400.	0.4	26
33	A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans. Journal of Lipid Research, 2017, 58, 752-762.	2.0	22
34	Lack of association of apoE Îµ4 allele with insulin resistance. Acta Diabetologica, 2012, 49, 25-32.	1.2	18
35	Acute presentation of Tangier polyneuropathy: a clinical and morphological study. Acta Neuropathologica, 1993, 86, 90-94.	3.9	16
36	Apolipoprotein (a) levels in type 1 and type 2 diabetes mellitus. Acta Diabetologica, 1991, 28, 158-161.	1.2	12

#	Article	IF	Citations
37	Impact of Baseline Glycemic Control on Residual Cardiovascular RiskÂin Patients With Diabetes Mellitus and Highâ€Risk Vascular Disease Treated With Statin Therapy. Journal of the American Heart Association, 2020, 9, e014328.	1.6	11
38	Increased receptor binding of low-density lipoprotein from individuals consuming a high-carbohydrate, low-saturated-fat diet. Metabolism: Clinical and Experimental, 1992, 41, 1154-1160.	1.5	10
39	Influence of breast- and formula-feeding on plasma cholesterol precursor sterols throughout the first year of life. Journal of Pediatrics, 1997, 131, 928-931.	0.9	10
40	Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian population. Haematologica, 2006, 91, 1613-20.	1.7	10
41	Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial. Diabetes and Vascular Disease Research, 2019, 16, 171-177.	0.9	9
42	The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care, 2020, 43, e22-e24.	4.3	9
43	Lipoprotein profile after combined kidney-pancreas transplantation in insulin-dependent diabetes mellitus. Transplant International, 1995, 8, 190-195.	0.8	8
44	Molecular study of human herpesvirus 6 and 8 involvement in coronary atherosclerosis and coronary instability. Journal of Medical Virology, 2012, 84, 1961-1966.	2.5	7
45	Diagnostic sensitivity of thyroid autoantibodies assessed in a population-based, cross-sectional study in adults. Autoimmunity Highlights, 2010, 1, 83-86.	3.9	3
46	Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With Highâ€Risk Vascular Disease: Insights From the ACCELERATE Trial. Journal of the American Heart Association, 2019, 8, e013790.	1.6	3
47	Understanding the physiological and functional consequences of menopause: The PROSALMEN study. Aging Clinical and Experimental Research, 2002, 14, 170-177.	1.4	0